Vaporized mebufotenin leads to improvement in treatment‐resistant depression
The Brown University Psychopharmacology Update June 28, 2026 DOI: 10.1002/pu.31471 (opens in new tab) via OpenAlex
Summary
AI-generated from the abstractA phase 2b trial found that a single, individualized vaporized dose of the psychedelic mebufotenin (5-MeO-DMT) improved depressive symptoms more than placebo in adults with treatment-resistant depression over seven days. No serious adverse events occurred during the study. The results were published in JAMA Psychiatry.
Study at a glance
| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Population | Adults with treatment-resistant depression |
| Duration | 7-day study |
| Topics | Anxiety |
| Keywords | Depression economics Adverse effect Dosing Regimen Clinical trial |
| Key finding | An individualized one-day dosing regimen of vaporized 5-MeO-DMT was more effective than placebo in improving depressive symptoms. |
Abstract
An individualized one‐day dosing regimen of a vaporized formulation of the psychedelic mebufotenin (5‐methoxy‐ N,N ‐dimethyltryptamine; 5‐MeO‐DMT) was more effective than placebo in improving depressive symptoms in adults with treatment‐resistant depression, a Phase 2b trial has found. No serious treatment‐emergent adverse events were reported during the 7‐day study. Results were published online March 2, 2026 in JAMA Psychiatry .